Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Non-Current Deffered Revenue (2020 - 2025)

Definitive Healthcare (DH) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 7346.88% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Dec 2025, up 7346.88%, and an annual FY2025 reading of $2.4 million, up 7346.88% over the prior year.
  • Non-Current Deffered Revenue was $2.4 million for Q4 2025 at Definitive Healthcare, up from $40000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.8 million in Q1 2025 and bottomed at $4000.0 in Q2 2024.
  • Average Non-Current Deffered Revenue over 5 years is $466833.3, with a median of $193000.0 recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue crashed 97.33% in 2024, then skyrocketed 30900.0% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $412000.0 in 2021, then crashed by 42.72% to $236000.0 in 2022, then crashed by 96.19% to $9000.0 in 2023, then surged by 255.56% to $32000.0 in 2024, then soared by 7346.88% to $2.4 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for DH at $2.4 million in Q4 2025, $40000.0 in Q3 2025, and $574000.0 in Q2 2025.